HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hajime Asahina Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2022Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
11/2021First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
1/2021Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
1/2021A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
1/2021Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
12/2019A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
1/2019Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
1/2019CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
12/2018A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
6/2018Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hajime Asahina Research Topics

Disease

21Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 09/2004
17Neoplasms (Cancer)
01/2021 - 01/2005
9Lung Neoplasms (Lung Cancer)
02/2016 - 07/2006
7Disease Progression
01/2021 - 03/2007
6Adenocarcinoma of Lung
01/2019 - 07/2006
3Interstitial Lung Diseases (Interstitial Lung Disease)
12/2019 - 01/2005
2Neoplasm Metastasis (Metastasis)
01/2019 - 07/2006
2Hypertension (High Blood Pressure)
04/2017 - 06/2012
2Adenocarcinoma
12/2006 - 01/2005
1Pneumonia (Pneumonitis)
11/2021
1Malignant Mesothelioma
01/2020
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
01/2020
1Venous Thromboembolism
06/2018
1Fever (Fevers)
04/2017
1Headache (Headaches)
04/2017
1Thymoma (Thymic Carcinoma)
12/2014
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
05/2014
1Dermatitis
09/2013
1Thymus Neoplasms (Thymus Neoplasm)
06/2012
1Breast Neoplasms (Breast Cancer)
06/2012
1Sarcoma (Soft Tissue Sarcoma)
06/2012
1Proteinuria
04/2012
1Hypertriglyceridemia
04/2012
1Stomatitis
04/2012
1Neutropenia
04/2012
1Nausea
03/2012
1Lymphopenia (Lymphocytopenia)
03/2012
1Lung Diseases (Lung Disease)
03/2012
1Leukopenia
03/2012
1Polycystic Kidney Diseases (Polycystic Kidney Disease)
12/2007
1Meningitis
12/2007
1Chronic Kidney Failure (Chronic Renal Failure)
12/2007
1Diplopia (Double Vision)
12/2007

Drug/Important Bio-Agent (IBA)

9ErbB Receptors (EGF Receptor)IBA
11/2021 - 01/2005
8Carboplatin (JM8)FDA LinkGeneric
01/2021 - 09/2004
7Gefitinib (Iressa)FDA Link
01/2010 - 01/2005
4osimertinibIBA
11/2021 - 01/2019
4Tyrosine Kinase InhibitorsIBA
01/2021 - 12/2006
3Pemetrexed (MTA)FDA Link
01/2021 - 12/2018
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
10/2018 - 09/2013
3amrubicinIBA
12/2014 - 04/2012
2PlatinumIBA
01/2021 - 12/2014
2Erlotinib Hydrochloride (CP 358,774)FDA Link
12/2018 - 11/2017
2AntibodiesIBA
03/2016 - 02/2016
2AnthracyclinesIBA
12/2014 - 05/2014
2Paclitaxel (Taxol)FDA LinkGeneric
08/2012 - 09/2004
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2006 - 01/2005
1AfatinibIBA
01/2022
1Immune Checkpoint InhibitorsIBA
01/2021
1NivolumabIBA
01/2020
1Inosine Triphosphate (ITP)IBA
01/2020
1130-nm albumin-bound paclitaxelIBA
12/2019
1Chemokine ReceptorsIBA
01/2019
1Phosphotransferases (Kinase)IBA
01/2019
1dabrafenibIBA
01/2019
1Bevacizumab (Avastin)FDA Link
12/2018
1edoxabanIBA
06/2018
1RamucirumabIBA
04/2017
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
04/2017
1necitumumabIBA
11/2016
1CytokinesIBA
03/2016
1LigandsIBA
03/2016
1B7-H1 AntigenIBA
02/2016
1Dasatinib (BMS 354825)FDA Link
10/2015
1(+)-JQ1 compoundIBA
10/2015
1Discoidin Domain Receptor 2IBA
10/2015
1CH 4987655IBA
06/2015
1RO5126766IBA
09/2013
1Creatine Kinase (Creatine Phosphokinase)IBA
09/2013
1Mechanistic Target of Rapamycin Complex 1IBA
06/2013
1(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA
06/2013
1Insulin-Like PeptidesIBA
08/2012
1figitumumabIBA
08/2012
1linifanibIBA
06/2012
1Pharmaceutical PreparationsIBA
04/2012
1amrubicinolIBA
04/2012
1ridaforolimusIBA
04/2012
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
03/2012
1Poly(ADP-ribose) Polymerase InhibitorsIBA
03/2012
1SteroidsIBA
03/2012
1Anti-Bacterial Agents (Antibiotics)IBA
03/2012
1olaparibIBA
03/2012
1CreatinineIBA
03/2012
1locked nucleic acidIBA
01/2012
1Peptide Nucleic AcidsIBA
01/2012
1NucleotidesIBA
12/2007
1AmylasesFDA Link
07/2006
1Biological ProductsIBA
07/2006

Therapy/Procedure

13Therapeutics
11/2021 - 03/2012
6Drug Therapy (Chemotherapy)
01/2021 - 01/2010
1Radiotherapy
01/2021
1Renal Dialysis (Hemodialysis)
12/2007